期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 10, 期 5, 页码 709-722出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERA.09.190
关键词
angiogenesis; beta-catenin; Bmi1; brain tumors; cancer stem cells; EGF; glioblastoma; miRNA; neural stem cells; notch; PDGF; receptor tyrosine kinases; signaling; Sonic hedgehog; VEGF; Wnt
类别
资金
- Joanna Bruner Brain Tumor Research Foundation
- Stephen E and Catherine Pappas Foundation
- NIH [K-12, K-08, CA 124804]
- Sontag Foundation
- James S McDonnell Foundation
- Adnexus
- Bristol-Myers Squibb
- Novartis
- NATIONAL CANCER INSTITUTE [K08CA124804] Funding Source: NIH RePORTER
The field of cancer research has experienced significant momentum from the discovery that most malignant tumors harbor subpopulations of cancer cells with stem cell features. Consequently, identification and characterization of so-called 'cancer-initiating cells' or 'cancer stem cells' has also provided novel insights into the biology of malignant brain tumors. Despite an ongoing debate regarding the exact role and identity of cancer stem cells, several studies have suggested that this subpopulation is critical for tumor initiation, tumor progression, angiogenesis and resistance to available therapies. The study of signaling pathways critical to normal neural stem and progenitor cells has also increased our understanding of the mechanisms that drive cancer stem cell-associated tumorigenesis and tumor progression. Novel treatment strategies are being developed to selectively target the molecular pathways relevant to cancer stem cells. This review summarizes important signaling pathways employed by both normal and cancer stem cells and highlights promising molecular-targeted therapies interfering with those signaling pathways in malignant gliomas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据